Genmab A/S
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GMAB | 9969.HK | 9966.HK | 0A3M.IL | 9926.HK | 2616.HK | |
|---|---|---|---|---|---|---|
| Market cap | 33.89B | 21.56B | 6.43B | 25.17B | 80.92B | 8.98B |
| P/E (TTM) | 43.4 | 20.3 | — | 5.1 | — | — |
| Forward P/E | 34.9 | 53.2 | -21.0 | 5.1 | 60.4 | 137.0 |
| Price/book | 5.5 | 1.9 | 3.3 | 1.1 | 8.1 | 5.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +91.12% | −14.61% | −39.84% | −13.17% | −27.63% | −7.84% |
| Today | −0.72% | +1.33% | +1.68% | +2.81% | +6.48% | +4.16% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GMAB news ›Genmab A/S (NASDAQ:GMAB) vs. Novavax (NASDAQ:NVAX) Critical Survey
Posted by Sarita Garza on Oct 31st, 2026 Novavax (NASDAQ:NVAX – Get Free Report) and Genmab A/S (NASDAQ:GMAB – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on…
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $57.00
Posted by Michael Walen on Oct 30th, 2026 Genmab A/S (NASDAQ:GMAB – Get Free Report) had its price target boosted by investment analysts at Morgan Stanley from $42.00 to $57.00 in a note issued to investors on Friday, Benzinga reports. The…
Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript
Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards October 28, 2026 12:00 PM EDT Jan van de Winkel - Co-Founder, President & CEOTahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of…
Genmab A/S: Relative Strength Chart - Stock Nasdaq Copenhagen
Compare Genmab A/S with the company of your choice via a Relative Strength chart. Real-time GMAB price, Nasdaq Copenhagen stock exchange Relative Strength Chart Genmab A/S Biotechnology & Medical Research All financial news and data…
Genmab A/S Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival With Petosemtamab Plus Pembrolizumab In First-Line Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma
Published on 10/26/2026 at 12:21 pm EDT As of May 15, 2026, median duration of follow-up was 25.5 months; clinical activity was observed across combined positive PD L-1 expression levels and p16 subgroups. With more mature follow-up, the…
Genmab A/S (0MGB) Receives a Buy from Barclays
In a report released today, James Gordon CFA from Barclays maintained a Buy rating on Genmab A/S, with a price target of DKK3,100.00. According to TipRanks, Gordon CFA is ranked #3195 out of 12442 analysts. In a report released on October…
Funds from operations of Genmab A/S – XETR:GE9
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the…
Critical Analysis: Genmab A/S (NASDAQ:GMAB) versus Cardio Diagnostics (NASDAQ:CDIO)
Genmab A/S (NASDAQ:GMAB – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their…
Genmab A/S (NASDAQ:GMAB) Given New $50.00 Price Target at HC Wainwright
Genmab A/S (NASDAQ:GMAB – Get Free Report) had its price objective increased by stock analysts at HC Wainwright from $40.00 to $50.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy”…
Genmab A/S Stock 12‑Month Price Target Raised to $42, Implies 9% Upside
TradingView Genmab A/S Stock 12‑Month Price Target Raised to $42, Implies 9% Upside - According to estimates from 21 analysts, Genmab A/S stock's average price target has risen from $41.45 to $42, with forecasts ranging from $3
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net3
- markets.businessinsider.com3
- themarketsdaily.com2
- tradingview.com2
- marketscreener.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.